November 26, 2019 09:19 AM ESTUpdated November 26, 11:40 PM
Bioregnum
R&D
Opinion

There’s one end­point that the boom­ing bio­phar­ma in­dus­try has failed at mis­er­ably: fi­nan­cial tox­i­c­i­ty

One of the big themes in R&D over the past few years has been the on­slaught of spend­ing on de­vel­op­ing new on­col­o­gy drugs. The FDA …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times